<SEC-DOCUMENT>0001279569-17-001474.txt : 20170721
<SEC-HEADER>0001279569-17-001474.hdr.sgml : 20170721
<ACCEPTANCE-DATETIME>20170721085030
ACCESSION NUMBER:		0001279569-17-001474
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170721
FILED AS OF DATE:		20170721
DATE AS OF CHANGE:		20170721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ESSA Pharma Inc.
		CENTRAL INDEX KEY:			0001633932
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37410
		FILM NUMBER:		17975529

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
		BUSINESS PHONE:		(778) 331-0962

	MAIL ADDRESS:	
		STREET 1:		SUITE 720
		STREET 2:		999 WEST BROADWAY
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V5Z 1K5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>essa6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Report of Foreign Private Issuer
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16
</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>For the month of July
2017</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Commission File Number 001-37410
</B></P>

<P STYLE="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>ESSA Pharma Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Translation of registrant&rsquo;s
name into English) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Suite 720, 999 West Broadway,
Vancouver, British Columbia, Canada, V5Z 1K5 </B></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F </FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> Form 40-F </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 12pt 0 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS INCLUDED AS PART OF THIS
REPORT </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 87%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: bold 8pt/107% Calibri, Helvetica, Sans-Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit(s)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">News Release Dated July 21, 2017: ESSA Pharma Announces Receipt of NASDAQ Notice of Market Value Deficiency</FONT></P>


</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; text-align: center; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt"><B><I>E</I></B></FONT><B><I><FONT STYLE="font-size: 7.5pt">SSA</FONT><FONT STYLE="font-size: 10pt">
        P</FONT><FONT STYLE="font-size: 7.5pt">HARMA</FONT><FONT STYLE="font-size: 10pt"> I</FONT><FONT STYLE="font-size: 7.5pt">NC</FONT><FONT STYLE="font-size: 10pt">.</FONT></I></B></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    July 21, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt; border-bottom: black 0.75pt solid"><FONT STYLE="font-size: 10pt">/</FONT><FONT STYLE="font-size: 7.5pt">S</FONT><FONT STYLE="font-size: 10pt">/
        D</FONT><FONT STYLE="font-size: 7.5pt">AVID</FONT><FONT STYLE="font-size: 10pt"> W</FONT><FONT STYLE="font-size: 7.5pt">OOD</FONT></P></TD></TR>
<TR>
    <TD COLSPAN="3" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Name:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Title:</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">David Wood</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 1pt">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JULY 21, 2017
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>&nbsp;</B><IMG SRC="essalogo.jpg" ALT="https:||mma.prnewswire.com|media|489324|ESSA_Pharma_Inc_ESSA_to_Present_at_Bloom_Burton___Co_Healthcare.jpg" STYLE="height: 111px; width: 338px"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>ESSA Pharma Announces Receipt of NASDAQ Notice of Market
Value Deficiency</B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">HOUSTON and VANCOUVER, July 21, 2017 /CNW/ - ESSA Pharma Inc.
(TSX:EPI; NASDAQ:EPIX) (&quot;ESSA&quot; or the &quot;Company&quot;), a clinical-stage pharmaceutical company focused on the development
of novel small molecule drugs for the treatment of prostate cancer, announced today that it has received written notification (the
&quot;Notification Letter&quot;) from The NASDAQ Stock Market LLC (&quot;Nasdaq&quot;) notifying the Company that it is not in
compliance with the minimum market value of listed securities requirement set forth in Nasdaq Rules for continued listing on The
Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires listed securities to maintain a minimum market value of US $35.0
million, and Listing Rule 5810(c)(3)(C) provides that a failure to meet the minimum market valuerequirement exists if the deficiency
continues for a period of 30 consecutive business days. Based on the market value of the Company's common shares for the 30 consecutive
business days from June 7, 2017, the Company no longer meets the minimum bid price requirement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Notification Letter does not impact the Company's listing
on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided
180 calendar days, or until January 16, 2018, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance, the
Company's common shares must have a market value of at least US $35.0 million for a minimum of 10 consecutive business days. In
the event the Company does not regain compliance by January 16, 2018, the Company may be eligible for additional time to regain
compliance.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Company intends to monitor the market value of its common
shares between now and January 16, 2018 and intends to cure the deficiency within the prescribed grace period. During this time,
the Company's common shares will continue to be listed and trade on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Company's business operations are not affected by the
receipt of the Notification Letter.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">The Company is also listed on the TSX and the Notification
Letter does not affect the Company's compliance status with such listing.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About ESSA Pharma Inc. </B><BR>
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castrate
resistant prostate cancer (&quot;CRPC&quot;) in patients whose disease is progressing despite treatment with current therapies.
ESSA believes that its product candidate, EPI-506, can significantly expand the interval of time in which patients suffering from
CRPC can benefit from hormone-based therapies. Specifically, EPI-506 acts by disrupting the androgen receptor (&quot;AR&quot;)
signaling pathway that drives prostate cancer growth. EPI-002, the primary metabolite of EPI-506, prevents AR transcriptional activity
by binding selectively to the N-terminal domain (&quot;NTD&quot;) of the AR. A functional NTD is essential for transactivation
of the AR. In preclinical studies, blocking the NTD has demonstrated the capability to overcome the known AR-dependent mechanisms
of CRPC. ESSA was founded in 2009.&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>About Prostate Cancer </B><BR>
Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide
(Globocan, 2012). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen
action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical
or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally
represents a transition to the lethal variant of the disease, mCRPC, and most patients ultimately succumb to the illness. The treatment
of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed
to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide,
or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease
progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies,
ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies
are no longer effective.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0"><B>Forward-Looking Statement Disclaimer</B><BR>
<I>This release contains certain information which, as presented, constitutes &quot;forward-looking information&quot; within the
meaning of the Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities laws. Forward-looking information
involves statements that relate to future events and often addresses expected future business and financial performance, containing
words such as &quot;determined&quot;, &quot;expect&quot;, and &quot;intend&quot;, statements that an action or event &quot;may&quot;,
&quot;might&quot;, &quot;could&quot;, &quot;should&quot;, or &quot;will&quot; be taken or occur, or other similar expressions and
includes, but is not limited to, statements about the future compliance with Nasdaq's minimum market value of listed securities
requirement including the intentions of the Company in response to the receipt of the Notification Letter. Forward-looking statements
and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA
to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those
expressed or implied thereby. Such statements reflect ESSA's current views with respect to future events, are subject to risks
and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA
as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive,
political and social uncertainties and contingencies. In making forward looking statements, ESSA may make various material assumptions,
including but not limited to (i) the accuracy of ESSA's financial projections; (ii) the Phase 1 portion of the Phase 1/2 clinical
trial proceeding as expected; (iii) obtaining positive results of clinical trials; (iv) obtaining necessary regulatory approvals;
and (v) general business, market and economic conditions. Forward-looking information is developed based on assumptions about such
risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 14, 2016 under the
heading &quot;Risk Factors&quot;, a copy of which is available on ESSA's profile at the SEDAR website at www.sedar.com, ESSA's
profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile. Forward-looking statements
are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation
to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may
be required by applicable Canadian and United States securities laws. Readers are cautioned against attributing undue certainty
to forward-looking statements. </I></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">SOURCE ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">View original content with multimedia: http://www.newswire.ca/en/releases/archive/July2017/21/c4171.html</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">%CIK: 0001633932</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information:</B> David S. Wood, Chief Financial Officer,
Tel: (778) 331-0962</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CO: ESSA Pharma Inc</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 9.75pt 0">CNW 07:30e 21-JUL-17</P>



<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>essalogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 essalogo.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0(L4&AO=&]S:&]P(#,N,  X0DE-! 0
M     A < G@ +$534T$@4&AA<FUA($EN8RX@*$-.5R!'<F]U<"]%4U-!(%!H
M87)M82!);F,I' ):  =(3U535$].' )T 'U4:&ES(&EM86=E(&UU<W0@8F4@
M=7-E9"!W:71H:6X@=&AE(&-O;G1E>'0@;V8@=&AE(&YE=W,@<F5L96%S92!I
M="!A8V-O;7!A;FEE9"X@4F5Q=65S="!P97)M:7-S:6]N(&9R;VT@:7-S=65R
M(&9O<B!O=&AE<B!U<V5S+AP"90  ' )0  A(86YD+6]U=!P"7P "5%@< AD
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M&#*"D946-T)2559B<G62E*&QL]'3(T-4@Y/2%R0E)C,X8\$T-453HK*T_\0
M' $!  (# 0$!              4& P0' @$(_\0 .Q$  0," @8'!P0!! ,
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M5K]/1L+;+_E0N#XZ,/B=&8]*YOMM^"K8-TW53_EU=_;:G_'=_%/+J[^VU/\
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M-HX[>_G=6SM<TM#FG<'L(Y[K#YAEF,XI;GUV1WV@MD#&[\554-83X-:3NX^
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M=8^_(ZE9SH/F,6>Z2V3*&N;UU92@536_83L\R4>'GM/L(6WJ(WN:6;<%3>L
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,1$1$1$1$1$1$1?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
